-
2024-513396-41-00
5
2019-05-15
PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR N
-
2024-511781-37-00
4
2019-04-16
YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIG
-
2024-510985-17-00
4
2019-03-14
First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive
-
2023-503812-34-00
4
2019-02-13
Locally Advanced or Metastatic Disease in Solid Tumors
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2023-510517-26-00
9
2018-10-26
Acute Myeloid Leukemia
-
2024-512049-17-00
6
2018-09-05
Newly diagnosed MM patients >= 65 years old or ineligible for autologo
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-514686-19-00
4
2017-03-10
Relapsed or Refractory Chronic Lymphocytic Leukemia
-
2023-507889-89-00
5
2016-02-19
Respiratory tract infection
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2023-505981-26-00
5
2015-11-20
Non−Small Cell Lung Cancer
-
2024-515283-31-00
6
2015-07-30
This study is designed to accept patients with varied disease origins,
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2024-511640-11-00
5
2014-05-15
Follicular lymphoma
-
2024-515152-20-00
4
2023-03-02
Stage III and high-risk stage II resected colon cancer patients.
-
2023-506136-32-00
9
2020-10-12
Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (
-
2024-518461-10-00
5
2026-01-12
WHIM Syndrome
-
2025-521107-42-00
4
2025-11-25
Alzheimer's Disease
-
2025-521451-23-00
5
2025-09-03
Subjects scheduled for elective colonoscopy performed according to ESG